4/5/2015 — About a week ago, the Food and Drug Administration (FDA), which regulates all drug products in this country, including homeopathic medicines, announced a 2 day public hearing which will take place on April 20th and 21st in Maryland.

The announcement can be found here:  www.federalregister.gov/articles/2015/03/27/2015-07018/homeopathic-product-regulation-evaluating-the-food-and-drug-administrations-regulatory-framework.

In the announcement, a number of issues have been raised.  The homeopathic community has been preparing for this for some time, and since the announcement there has been quite a bit of additional preparation taking place.

There are some in the community who believe that there is an unstated agenda, and even if this is not the case, there are virulent anti-homeopathic medicine detractors out there who will seize any opportunity to denigrate homeopathic practice.

I’m writing you in the hopes that you will take the time to send written comments on your experience with homeopathy to the FDA.

I think that what is important to be said by homeopathic patients is that they have experienced benefit from these medicines (only if that is true for you, of course), and that you consider your access to bona-fide, regulated products at the “over-the-counter” level as well as from your homeopathic practitioner.

These do not need to be long or detailed.  It is by sheer volume that such letters may succeed.

To submit electronically, go to:  www.regulations.gov

To submit written comments, send them to:  Division of Dockets Management (HFA-305),

Food and Drug Administration, 5630 Fishers Lane, rm. 1061,

Rockville, MD 20852

In both cases, refer to [Docket No. FDA-2015-N-0540] in the header of your email or at the top of your written comments.

The announcement itself also contains information on the live webcast of the event, as well as on the availability of transcripts.

Please circulate this notice to anyone whom you think may be interested in responding.

Thank you in advance for your help.

Dr. Shevin